FDA Approves T-DXd for 2 New Indications in Early-Stage HER2-Positive Breast CancerByJason M. BroderickMay 16th 2026
Early-Onset Cancer Care: First Insights from the BRIDGE ProgramByW. Kimryn Rathmell, MD, PhDMay 16th 2026
VIKTORIA-2 Trial Evolves to Evaluate Gedatolisib in Endocrine-Sensitive and -Resistant Breast CancerBySabrina SeraniMay 15th 2026
Lessons in Multidisciplinary Oncology: Implementation of the BRIDGE ProgramByW. Kimryn Rathmell, MD, PhDMay 14th 2026